HROC450Met1 T0 M1 Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The HROC (Hansestadt Rostock Colorectal cancer) cell line panel comprises patient-derived colorectal cancer models developed from primary tumor tissue and/or matched metastatic lesions. These cell lines are frequently accompanied by corresponding patient-derived xenografts (PDXs) and organoids, enabling integrative modeling of colorectal cancer (CRC) in both in vitro and in vivo systems. HROC models preserve critical clinical and molecular diversity found in colorectal cancer, including variations in microsatellite instability (MSI vs. MSS) and key genetic drivers such as mutations in APC, KRAS, BRAF, PIK3CA, and TP53. Cultured as adherent epithelial monolayers and typically used at low passage numbers, HROC lines maintain phenotypic and genomic fidelity to their patient tumors, supporting translational relevance in drug and biomarker research. The nomenclature system for HROC cell lines provides detailed metadata on origin and experimental history. For example, “Tu” identifies cell lines derived from primary tumors, “Met” from metastatic lesions, while “T#” and “M#” indicate the number of PDX transfers and the specific mouse host, respectively. This systematic naming allows for easy tracking of matched sets, such as primary-metastasis pairs or in vitro-in vivo derivatives. These matched models support studies on clonal evolution, metastasis, therapy resistance, and pharmacokinetic behavior—including transporter expression and barrier integrity relevant for drug absorption. Cell lines undergo routine authentication (e.g., STR profiling) and are tested regularly for mycoplasma contamination. Characterization data for numerous HROC models are publicly available in Cellosaurus and in peer-reviewed publications. HROC cell lines are particularly valuable for subtype-stratified drug screening, biomarker discovery across MSI-H and MSS tumors, and mechanistic studies involving primary vs. metastatic disease. When paired with PDXs and/or organoids, they provide a robust platform for preclinical evaluation, including drug sensitivity testing and modeling of tumor-stroma or immune interactions. Due to their comprehensive annotation and clinical relevance, HROC models are suitable for both basic and translational research in colorectal cancer. |
|---|---|
| 生物體 | Human |
| 組織 | Metastasis |
| 疾病 | Colorectal Adenocarcinoma |
| 轉移部位 | Liver |
特徵
| 年齡 | 59 years |
|---|---|
| 性別 | Male |
| 生長特性 | Adherent |
監管數據
| 引用 | HROC450Met1 T0 M1 (Cytion catalog number 300725) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
生物分子資料
| MSI 狀態 | MSS |
|---|
處理方式
| 培養基 | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 解離試劑 | TrypLE Express 15 min 37°C |
| 傳代培養 | Seeding after thawing 4*104/cm² |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 300725-180825 | 分析證明書 | 22. Oct. 2025 | 300725 |